Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dibromotyrosine is a small molecule derivative of the natural amino acid tyrosine, characterized by the presence of two bromine atoms at positions 3 and 5 on the aromatic ring. It is classified as an antithyroid agent and has been used in medicine for the treatment of functional hyperthyroidism. Dibromotyrosine acts by interfering with thyroid hormone synthesis, likely through inhibition of iodination processes in thyroglobulin. It is also naturally produced by marine sponges and can be formed enzymatically via eosinophil peroxidase. In research settings, dibromotyrosine has demonstrated cytotoxic activity against certain cancer cell lines through induction of apoptosis mediated by mitochondrial dysfunction and oxidative stress; it may act as a topoisomerase II catalytic inhibitor and modulate signaling pathways such as IKK/NFκB. Its primary use remains investigational.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dibromotyrosine.